Metastatic lymph node targeted chemosensitivity test for gastric cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The objective of this study was to compare the chemosensitivity of primary tumor and metastasized lymph node from patient with gastric adenocarcinoma. Materials and Methods: We studied 26 gastric cancer patients with lymph node metastasis who underwent gastric resection at the Korea University Guro Hospital from Feb 2007 to July 2008. The chemosensitivity of primary tumor and metastatic lymph node were studied using an adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Results: The concordance rate of the ATP-CRA test was 30.8% (8/26). The concordance rate between primary tumor and metastatic N2 group lymph node was only 9.1% (1/11). The metastatic tumor inhibition rates with 5-fluorouracil, cisplatin, doxorubicin, and oxaliplatin were higher than the inhibition rates for primary tumor. Tumor inhibition rates was significantly different between primary tumor and metastatic tumor after doxorubicin treatment (27.734 ± 20.95 versus 38.403 ± 26.87, P = 0.021). We detected simple correlations of tumor inhibition rates between primary and metastatic tumors with cisplatin (r = 0.661, P < 0.001) and doxorubicin (r = 0.475, P = 0.031). Conclusions: We observed differences between first choice chemotherapeutic agents based on ATPCRA tests of primary tumor and metastatic tumor in lymph node. Therefore, chemotherapeutic agents should be carefully selected for adjuvant chemotherapy using a chemosensitivity test.

Original languageEnglish
Pages (from-to)657-662
Number of pages6
JournalJournal of Surgical Research
Volume171
Issue number2
DOIs
Publication statusPublished - 2011 Dec

Keywords

  • chemosensitivity test
  • gastric cancer
  • tumor heterogeneity

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Metastatic lymph node targeted chemosensitivity test for gastric cancer'. Together they form a unique fingerprint.

  • Cite this